TRVI

Trevi Therapeutics, Inc. (TRVI) - Q1 2026 Filing Summary

Business Context and Reporting Period

This Form 10-Q covers the quarterly period ended March 31, 2026. Trevi Therapeutics is a clinical-stage biopharmaceutical company developing Haduvio (oral nalbuphine ER) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease (non-IPF ILD), and refractory chronic cough (RCC). The company has no product revenue and operates as a single reportable segment.

Key Financial Metrics

Material Changes vs. Prior Period

• Increased Operating Loss: Net loss increased by $2.9 million (27.6%) year-over-year, driven by higher operating expenses.
• R&D Expense Growth: R&D expenses rose by $2.1 million, primarily due to increased clinical development costs for Phase 1 NDA supportive studies, Phase 3 IPF trials, and the Phase 2b RCC trial, partially offset by decreases in Phase 2b CORAL and Phase 2a RIVER trial costs.
• G&A Expense Growth: G&A expenses increased by $1.3 million, attributed to higher legal fees for intellectual property filings, increased stock-based compensation, and personnel costs.
• Investing Activities: Net cash provided by investing activities turned positive ($17.0 million) compared to a net use of $10.0 million in the prior year, driven by $25.6 million in proceeds from maturities of marketable securities.
• Stock-Based Compensation: Total stock-based compensation increased to $2.2 million from $1.2 million.

Outlook, Guidance, and Risks

• Clinical Pipeline Progress:
  • IPF: Positive Phase 2b CORAL trial results announced in June 2025. Two pivotal Phase 3 trials are planned to initiate in 2026, with topline results expected in 2027 and 2028.
  • RCC: Positive Phase 2a RIVER trial results announced in March 2025. A Phase 2b trial is expected to initiate in Q2 2026.
  • Non-IPF ILD: An adaptive Phase 2b trial is planned for initiation in H2 2026.
• Liquidity and Capital Resources: As of March 31, 2026, the company held $171.8 million in cash and marketable securities. Management believes this is sufficient to fund operations into 2030, covering development through potential FDA approval for IPF, but additional funding will be required for commercialization and full development of non-IPF ILD and RCC indications.
• Subsequent Event (Financing): On April 16, 2026, Trevi completed an underwritten public offering of 11.6 million shares at $13.00 per share, with the underwriters' option fully exercised. The offering generated approximately $173.4 million in gross proceeds (approx. $162 million net).
• Risks: The company remains pre-revenue and dependent on successful clinical outcomes and regulatory approvals. Failure to raise additional capital or achieve clinical milestones could force delays or discontinuation of programs.

Key Facts for Investor Verification

• Recent Capital Raise: Verify the impact of the April 2026 offering ($173.4M gross) on the company's cash runway and dilution profile.
• Cash Burn Rate: Monitor the quarterly cash burn (approx. $16.7M in Q1 2026) against the updated cash balance post-April financing.
• Clinical Trial Timelines: Confirm the initiation dates for the two Phase 3 IPF trials and the Phase 2b RCC trial scheduled for 2026.
• Stock-Based Compensation: Track the increasing trend in stock-based compensation ($2.2M in Q1 2026) as a component of operating expenses.
• Warrant and Option Dilution: Note the existence of 19.1 million shares reserved for warrants and 12.0 million shares reserved for stock options as of March 31, 2026.